Claims for Patent: 12,233,042

Summary for Patent: 12,233,042

Title:	Treatment of cutaneous disorders
Abstract:	Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
Inventor(s):	Howard Welgus, Matthew Gene Davidson, Jayson Michael Rieger
Assignee:	Verrica Pharmaceuticals Inc
Application Number:	US17/471,853
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,233,042
Patent Claims:	1. A composition comprising: cantharidin, wherein the composition comprises greater than or equal to 0.7 and less than or equal to 0.9 weight per weight percent of cantharidin; acetone, wherein the composition comprises greater than or equal to 55 and less than or equal to 65 weight per weight percent of acetone; ethanol, wherein the composition comprises greater than or equal to 25 and less than or equal to 35 weight per weight percent of ethanol; castor oil, wherein the composition comprises greater than or equal to 1.2 and less than or equal to 1.6 weight per weight percent of castor oil; nitrocellulose, wherein the composition comprises greater than or equal to 3 and less than or equal to 6 weight per weight percent of nitrocellulose; hydroxypropyl cellulose, wherein the composition comprises greater than or equal to 0.5 and less than or equal to 1 weight per weight percent of hydroxypropyl cellulose; and camphor, wherein the composition comprises greater than or equal to 0.5 and less than or equal to 1.5 weight per weight percent of camphor. 2. The composition of claim 1 further comprising denatonium benzoate, wherein the composition comprises greater than or equal to 0.001 and less than or equal to 0.01 weight per weight percent of denatonium benzoate. 3. The composition of claim 1 further comprising gentian violet, wherein the composition comprises greater than or equal to 0.0001 and less than or equal to 0.001 weight per weight percent of gentian violet. 4. The composition of claim 1, wherein the composition comprises greater than or equal to 58 and less than or equal to 62 weight per weight percent of acetone. 5. The composition of claim 1, wherein the composition comprises greater than or equal to 28 and less than or equal to 32 weight per weight percent of ethanol. 6. The composition of claim 2, wherein the composition comprises greater than or equal to 0.004 and less than or equal to 0.008 weight per weight percent of denatonium benzoate. 7. The composition of claim 3, wherein the composition comprises greater than or equal to 0.0002 and less than or equal to 0.0008 weight per weight percent of gentian violet. 8. A single use applicator device comprising the composition of claim 1. 9. A method of treating a subject having a skin lesion comprising administering the composition of claim 1 to at least a portion of the skin lesion. 10. The method of claim 9, wherein the skin lesion is molluscum contagiosum. 11. The method of claim 9, wherein the skin lesion is seborrheic keratosis, actinic keratosis, milia, age spots, porokeratosis, or skin cancer. 12. The method of claim 9, wherein the skin lesion is a wart. 13. The method of claim 12, wherein the wart is a common wart, plantar wart, or genital wart. 14. The method of claim 9, wherein at least a portion of the composition remains on the skin lesion for greater than or equal to 12 hours and less than or equal to 48 hours. 15. The method of claim 9, wherein the plasma concentration of cantharidin in the subject is less than or equal to 3.3 ng/ml after at least 12 hours after the administration step. 16. The method of claim 9, wherein at least a portion of the composition remains on the skin lesion for up to 24 hours. 17. The composition of claim 1 further comprising: denatonium benzoate, wherein the composition comprises greater than or equal to 0.001 and less than or equal to 0.01 weight per weight percent of denatonium benzoate; and gentian violet, wherein the composition comprises greater than or equal to 0.0001 and less than or equal to 0.001 weight per weight percent of gentian violet. 18. The method of claim 12, wherein the wart is a common wart. 19. The method of claim 12, wherein the wart is a plantar wart. 20. The method of claim 12, wherein the wart is a genital wart.